Health utilities in Alzheimer's disease: A survey of patients and caregivers in the United States
Journal of Alzheimer’s Disease · 2025
DOI: 10.1177/13872877251350381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Pei-Jung Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, U…. Hauptthemen laut MEDLINE: Caregivers, Alzheimer Disease, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Eli Lilly and Company, Eisai, Genentech.
Themen: Demenz
Abstract (Originalsprache)
Background
The introduction of new Alzheimer's disease (AD) treatments necessitates updated health utilities for economic evaluations.
Objective
Measure health utilities of US adults with mild cognitive impairment (MCI) and AD and their caregivers.
Methods
We conducted a web-based survey using the EuroQol EQ-5D-5L and Quality of Life in AD (QoL-AD), stratified by disease stage and care setting. Individuals with MCI or mild Alzheimer's dementia self-reported their utilities. Caregivers randomly received either a proxy survey to complete on behalf of the person with moderate to severe AD they cared for, or a caregiver survey that asked them to self-report their own utilities.
Results
We received 241 patient responses and 176 caregiver responses. Patient EQ-5D-5L scores decreased monotonically as disease severity increased, with a 0.55 utility difference between individuals with MCI and severe AD in the community setting. EQ-5D-5L values were generally lower for individuals residing in nursing homes (0.04 to 0.78) compared to those in community settings (0.22 to 0.77). Patients’ QoL-AD scores did not exhibit a consistent association with their disease severity. Similarly, caregivers’ EQ-5D-5L scores did not exhibit a monotonic trend with the patient's disease severity, although caregiver utilities were generally higher for those caring for someone in a nursing home than for those caring for patients in the community.
Conclusions
Our results contribute to improving AD economic evaluations by reflecting the lived experience of more contemporary populations and facilitating the value assessment of novel therapies that delay progression from MCI to more severe disease stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
- Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
- UsAgainstAlzheimer's, Washington, DC, USA.
ORCID-Profile: Pei-Jung Lin
Förderung
- Eli Lilly and Company
- Eisai
- Genentech
- Biogen
Zitieren
APA
Lin, P. J., Riley, A. G., Synnott, P. G., Frangiosa, T. L., Roniger, A., Neumann, P. J., & Cohen, J. T. (2025). Health utilities in Alzheimer's disease: A survey of patients and caregivers in the United States. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251350381
Vancouver
Lin PJ, Riley AG, Synnott PG, Frangiosa TL, Roniger A, Neumann PJ, et al. Health utilities in Alzheimer's disease: A survey of patients and caregivers in the United States. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877251350381
BibTeX
@article{Lin2025,
author = {Lin, Pei-Jung and Riley, Abigail G and Synnott, Patricia G and Frangiosa, Terry L and Roniger, Amber and Neumann, Peter J and Cohen, Joshua T},
title = {Health utilities in Alzheimer's disease: A survey of patients and caregivers in the United States},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
doi = {10.1177/13872877251350381}
}
EUVIMED